Drugs Made In America Acquisition Corp. (DMAA)

Price, with every insider trade on it

Closing prices, 12 months · point at a dot for who traded, or at the line for the close

10.85 on 9 Oct 2026

0 buys0 sales at will0 planned sales

Fiscal year 2025, ended 31 Dec 2025, as filed

Net income

$5.94M

Free cash flow

$539.19K

From Form 4, most recent first

Date	Insider	Type	Value	Of own stake
18 Feb 2025	Drugs Made In America Acquisition LLC 10% owner	Bought	n/a	0.7%
18 Feb 2025	Stockwell Lynn CEO and Exe. Chair of Board	Bought	n/a	0.7%
29 Jan 2025	Drugs Made In America Acquisition LLC 10% owner	Bought	n/a	4.1%
29 Jan 2025	Stockwell Lynn CEO and Executive COB	Bought	n/a	opened
29 Jan 2025	Drugs Made In America Acquisition LLC 10% owner	Sold at will	n/a	57.8%
29 Jan 2025	Stockwell Lynn CEO and Executive COB	Sold at will	n/a	57.8%

59out of 100

Profitability 100

Financial strength 17

Growth n/a

Insiders 50

Strongest on profitability (100), weakest on financial strength (17). A score of the business, not of the price.

Last 12 months

Only here

Bought

$0.00

0 buys, 0 buyers

Sold

$0.00

0 sales

Planned sales

n/a

under a 10b5-1 plan